Podcasts about Reproductive Sciences

When women think about the benefits of menopausal hormone therapy, things like hot flashes, insomnia and vaginal dryness come to mind.  But for many women, bone health is, or should be, at the top of the list.   In this episode, I speak with Dr. Risa Kagan about the role of estrogen, progesterone, and testosterone in bone health. Definition of Low Bone Mass (Osteopenia) and Osteoporosis The Difference Between a T score and a Z score  FRAX- Fracture Risk Assessment Tool When Bone Mass Peaks How to Maximize Bone Health Before Menopause Hits Role of Estrogen in Young Women The Danger Zone- When Most Women Lose the Majority of Their Bone Mass The Role of Birth Control Pills and Prevention of Bone Loss If Exercise is Enough The Relationship Between Hot Flashes and Osteoporosis Bone Loss Post Menopause Impact of Menopausal Estrogen Therapy on Bones Taking Menopausal Hormone Therapy (MHT) in the Absence of Hot Flashes to Protect Bones The Difference Between Bone Density and Bone Quality When it is Appropriate to Take an Anabolic Agent If the TYPE of Estrogen you take matters (Conjugated, Synthetic, Bioidentical) What DOSE of Estrogen is Needed to Prevent Fractures If it is Appropriate to Monitor Estradiol Blood Levels When Taking Transdermal MHT The Target Estradiol Level for Bone Health What Happens to Bone Density When MHT is Discontinued If MHT Should Be Taken Forever If Progestogens Plays a Role in Bone Health The Role of Bazodoxifene (Duovee™) in Bone Health The Role of TESTOSTERONE therapy in Bone Health Another Podcast with Dr. Kagan: When Progesterone is a Problem   Dr. Risa Kagan is a Clinical Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California San Francisco, and a consulting gynecologist with Sutter Health. Dr. Kagan has published over 100 scientific papers  on post menopause bone health and hormone therapy.  Dr. Streicher is on SUBSTACK      DrStreicher.Substack.com Articles Monthly newsletter All COME AGAIN podcast episodes Monthly News Flash Reports on recent research  Monthly Zoom Ask Me Anything Webinar   Information on Dr. Streicher's COME AGAIN Podcast- Sexuality and Orgasm Lauren Streicher MD, is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause, and a Senior Research Fellow of The Kinsey Institute, Indiana University. She is a certified menopause practitioner of The Menopause Society. She is the Medical Director of Community Education and Outreach for Midi Health.   Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.    LINKS Subscribe To Dr. Streicher's Substack Information About the COME AGAIN Podcast Dr. Streicher's CV and additional bio information To Find a Menopause Clinician and Other Resources  Glossary Of Medical Terminology Books by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy                                       Dr. Streicher's Inside Information podcast is for education and information and is not intended to replace medical advice from your personal healthcare clinician. Dr. Streicher disclaims liability for any medical outcomes that may occur because of applying methods suggested or discussed in this podcast.              

Welcome to a new season of Proverbs with Daisy Maskell. This season we are tackling some of life's most challenging conversations, with expert guests. Our first guest of the season is author, education, academic and scientist Professor Joyce Harper. Joyce is an Professor of Reproductive Science at University College London, Institute for Women's Health. Her most recent book, Your Fertile Years, explores women's health from puberty to menopause. On this weeks episode, Daisy and Professor Joyce talk about how fertility evolves with age, our societal misunderstandings about fertility and how to not let yourself be defined by your age. Follow Daisy Maskell - Instagram: https://www.instagram.com/daisylmaskell/ Twitter: https://twitter.com/daisy_maskell_ Thank you to our sponsors... Proverbs is brought to you by BetterHelp. Discover your relationship “green flags”, with BetterHelp. Visit BetterHelp.com/PDM today to get 10% off your first month. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textIs infertility really just a woman's issue? Gabriela Rosa, a renowned fertility expert and Harvard researcher, debunks common myths about conception and shares how over 140,000 couples have improved their fertility using her science-backed approach. From the 50/50 responsibility between men and women to the role of nutrition and lifestyle in conception, Gabriela offers practical strategies for optimizing fertility. This conversation also tackles miscarriage stigma, IVF struggles, and how healthcare often fails couples who are trying to conceive.

Reproductive health is historically understudied and underfunded in the United States. Scientists across Connecticut and beyond have been working to change that. Scientific initiatives like EndoRISE, a Connecticut-based program focused on advancing endometriosis research, are making strides toward better understanding reproductive health. This hour, we explore how President Trump’s recent funding cuts could impact their progress. GUESTS: Michayla Savitt: State Government Reporter, CT Public Dr. Danielle Luciano: Associate Professor of Obstetrics and Gynecology and co-director of EndoRISE Dr. Lubna Pal: Professor of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine Julie Rovner: Chief Washington Correspondent, KFF Support the show: http://wnpr.org/donateSee omnystudio.com/listener for privacy information.

Send us a textWelcome to the third episode of season five, in conversation with Professor Cynthia Gyamfi-Bannerman. Professor Gyamfi-Bannerman's BioDr. Gyamfi-Bannerman is Chair of the Department of Obstetrics, Gynecology, and Reproductive Sciences at UC San Diego Health, joining the faculty at UCSD in 2021. She holds the Samuel SC Yen Endowed Chair at UCSD and is a Professor with Tenure. She is board certified in both Obstetrics & Gynecology and Maternal-Fetal Medicine and focuses her career on obstetric complications with a primary focus on preterm birth prevention. Dr. Gyamfi is a proficient, NIH funded researcher whose research has focused on preterm birth prediction and prevention and in interventions to improve outcomes for those delivering preterm, namely antenatal corticosteroids. Results of her randomized clinical trial on antenatal corticosteroids in women at risk for late preterm birth were published in the New England Journal of Medicine and changed obstetric practice in the United States. She also conducts research in the areas of preeclampsia, infectious disease, maternal morbidity and health disparities with over 200 peer-reviewed publications.She is currently the Steering Committee Chair of a multi-center NIHLBI ENRICH study focused on improving maternal and childhood outcomes for pregnant individuals from poorly resources backgrounds, and Steering Committee Chair for the Preventing pre- eclampsia: Evaluating AspiRin Low-dose regimens following risk Screening (PEARLS study), assessing aspirin dosing in sub-Saharan Africa. Recently, she was elected to the American Society for Clinical Investigation, a national medical honor society. Finally, she serves on the NICHD Council.Aside from her clinical and research endeavors, Dr. Gyamfi is the Immediate Past President for the Society for Maternal-Fetal Medicine (SMFM), the national and international society representing all perinatologists after completing her President in February, 2025. She is actively involved in writing clinical guidelinesin obstetrics for both SMFM and the American College of Obstetricians and Gynecologists and continues to mentor trainees and junior faculty from around the world.https://providers.ucsd.edu/details/1568494250/obstetrics-gynecologyPodcast information:We have not included any patient identifiable information, and this podcast is intended for professional education rather than patient information (although welcome anyone interested in the field to listen). Please get in touch with feedback or suggestions for future guests or topics: conversationsinfetalmed@gmail.com, or via Twitter (X), Bluesky or Instagram via @fetalmedcast.Music by Crowander ('Acoustic romance') used under creative commons licence. Podcast created, hosted and edited by Dr Jane Currie. 

Juno is arguably the most well-known depiction of adoption in pop culture... but what messages does it really send about relinquishment, teen pregnancy, and reproductive justice? Is adoption truly the “perfect alternative” to abortion as Juno would have us believe, or does this charmingly complicated 2007 film gloss over the realities of birth mothers and family separation? This week, we're joined by Dr. Gretchen Sisson, sociologist and author of Relinquished: The Politics of Adoption and the Privilege of American Motherhood, to break down Juno's thorny politics on choice, motherhood, and adoption. GUEST DETAILS Gretchen Sisson, Ph.D., is a qualitative sociologist studying abortion and adoption at Advancing New Standards in Reproductive Health (ANSIRH) in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco. Her research was cited in the Supreme Court's dissent in Dobbs v. Jackson Women's Health Organization. She is the author of Relinquished: The Politics of Adoption and the Privilege of American Motherhood. CONNECT WITH US Instagram: @sexedwithdbpodcastTikTok: @sexedwithdbTwitter: @sexedwithdb Threads: @sexedwithdbpodcast YouTube: Sex Ed with DB ROM-COM VOM SEASON 11 SPONSORS: Lion's Den, Uberlube, Magic Wand, + Arya. Get discounts on all of DB's favorite things here! GET IN TOUCH Email: sexedwithdb@gmail.comSubscribe to our newsletter for behind-the-scenes content and answers to your sexual health questions! FOR SEXUAL HEALTH PROFESSIONALS Check out DB's workshop: "Building A Profitable Online Sexual Health Brand" ABOUT THE SHOW Sex Ed with DB is your go-to podcast for smart, science-backed sex education—delivering trusted insights from top experts on sex, sexuality, and pleasure. Empowering, inclusive, and grounded in real science, it's the sex ed you've always wanted. SEASON 11 TEAM Creator, Host & Executive Producer: Danielle Bezalel (DB) Producer: Sadie Lidji Communications Lead: Cathren Cohen Marketing Coordinator: Alex Bateman Logo Design: Evie Plumb (@cliterallythebest)

On This Episode We Discuss: In this episode we explore genetic testing in low risk populations, both in direct-to-consumer and clinical settings. We interview authors on two recent JoGC papers related to topics of communication of health risks, understanding of genetic testing, and informed decision-making. You can find the Journal of Genetic Counseling webpage via onlinelibrary.wiley.com or via the National Society of Genetic Counselors website.   Segment 1: An analysis of direct-to-consumer genetic testing portals and their communication of health risk and test limitations Nicole Lee is an associate professor of communication in the School of Social and Behavioral Sciences at Arizona State University. Her research examines the intersection of science communication, public relations, and digital media. This work has been applied to many contexts including climate change, biodiversity research, wellness products, and direct-to-consumer genetic testing. x: @lee_nicole linkedin: https://www.linkedin.com/in/nicoleleepr/   In this segment we discuss: - What motivated the exploration of how direct-to-consumer (DTC) genetic testing companies communicate health risks to consumers. - Potential impacts on consumers who may misinterpret relative risk when presented without adequate context. - Importance of genetic counselors in improving interpretation and communication of DTC genetic test results. - Suggestions for enhancing transparency and clarity in communicating health risks to consumers.   Segment 2: Non-Invasive Prenatal Screening: Testing Motivations and Decision Making in the Low-Risk Population Meagan Choates, MS, CGC is the Assistant Program Director of the University of Texas Genetic Counseling Program and Assistant Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the McGovern Medical School at UTHealth Houston where she practices prenatal genetic counseling. She received a BS in Biochemistry and Genetics with a Minor in Psychology from Texas A&M University in 2014 and an MS in Genetic Counseling from the University of Texas Genetic Counseling Program in 2016. Meagan provides prenatal genetic counseling services at several Houston area clinics, and supervises genetic counseling students while on their prenatal rotation. In addition, she directs and teaches the genetic counseling program's Embryology course and Approaches to Genetic Counseling Research I & II. She co-directs and teaches in the program's Prenatal Genetic Counseling, Psychosocial Issues, and Psychosocial Practicum courses. She additionally oversees the genetic counseling students' Master of Science thesis research process. Her personal research interests include understanding how genetic screening and testing options are discussed, utilized, and interpreted in the clinical setting. ResearchGate profile: https://www.researchgate.net/profile/Meagan-Choates-2 In this segment we discuss: - The anecdotal observations that inspired the study, notably that low-risk and high-risk patients shared similar motivations for choosing NIPT. - That insurance coverage was the second most significant factor influencing the decision to undergo NIPT. - About 44% of participants were classified as making "uninformed decisions" despite receiving pre-test counseling from a genetic counselor. However, the term “uninformed” used by the MMIC tool can be misleading. - The challenge of balancing detailed knowledge expectations with patients' ability to make value-consistent and thoughtful decisions.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

Send us a textIn this episode of Causes or Cures, Dr. Eeks sits down with Professor Joyce Harper to discuss her fascinating study on the effects of cold water swimming on premenstrual and perimenopausal symptoms. Prof. Harper kicks off by sharing her background and what inspired her to dive into this unique research. They explore what qualifies as cold water swimming and how the study was conducted, revealing interesting findings—like the differences in benefits between wearing bathing suits versus wetsuits and the optimal time women spent in cold water. The conversation delves into the potential physical and mental effects of cold water exposure and why it might alleviate certain symptoms. To wrap up, Prof. Harper offers insightful advice on aging gracefully and happily.Professor Joyce Harper is an acclaimed author, researcher, and award-winning Professor of Reproductive Science at University College London's Institute for Women's Health. With nearly 40 years of experience in fertility, genetics, and women's health, she founded Reproductive Health at Work, leads the Reproductive Science and Society Group, and co-leads InTune, a UK-based menopause education and support program.*New* SUBSCRIBE for Causes or Cures+ Bonus Episodes!You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here.Support the show

Soul Pitt Media Health & Business Report Episode #87 | Interview with Alexander B. Olawaiye, MD | Professor / Department of Obstetrics / Gynecology and Reproductive Sciences at UPMC Join Craig as he discusses with Dr. Olawaiye: 1) Dr. Olawaiye, growing up in Nigeria, did you always dream of being a physician? 2) After you completed medical school in London, what made you want to come to the United States? 3) Dr. Olawaiye, what advice can you give our younger listeners who may want to pursue a medical career? Additionally, make sure you listen to our Community Calendar (brought to you by Pittsburgh Regional Transit, PRT) with Debbie Norrell at the end of each of our interviews so you can keep up with what's going on in our Pittsburgh region. Soul Pitt Media's Health & Business Report is sponsored by UPMC, Pittsburgh Regional Transit (PRT), Duquesne Light Co., Allegheny County Health Department, Pennsylvania's Children's Health Insurance Program (CHIP), and Central Outreach Wellness Center.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Alessandro Santin to discuss Sacituzumab Govitecan (TROPiCS—03) in Advanced Endometrial Cancer. Dr. Alessandro D. Santin, a native of Italy, graduated with honors from the University of Brescia, Italy and received his postgraduate training in Obstetrics & Gynecology at the same University. He served a fellowship in Gynecologic Oncology at the University of California, Irvine and an International Fellowship in the Division of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, Arkansas. Dr. Santin joined the faculty in the Section of Gynecologic Oncology in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale University as Professor as of July 2008. Dr. Santin has more than 400 original research and peer-reviewed publications including multiple review articles and book chapters and he has written extensively on various topics, including cancer of the ovary, endometrium and cervix as well as on tumor immunology and immunotherapy. Dr. Santin's clinical interests include the use of immunotherapy in ovarian, cervical and endometrial carcinoma patients with disease resistant/refractory to standard treatment, therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the development of personalized treatment modalities including monoclonal antibodies and antibody-drug-conjugates (ADC) against chemotherapy resistant gynecologic tumors. Highlights: In the TROPiCS-03 trial Sacituzumab Govitecan demonstrated encouraging clinical activity in recurrent endometrial cancer patients in progression after chemotherapy and immune check point inhibitors Sacituzumab Govitecan toxicity profile was manageable with only 5% of patients discontinuing treatment due to TRAEs TROP-2 protein was expressed in over 90% of endometrial cancer patients enrolled in the TROPiCS-03 trial and showed limited correlation with efficacy to Sacituzumab Govitecan

Pregnancy can be a transformational time of hope and change. But many people are especially vulnerable during pregnancy, with factors that put them and their babies at greater risk for health complications than others. In this episode, we focus on solutions that can improve a person's pregnancy, birthing experience, and recovery with two guests: Dr. Hyagriv Simhan, professor and executive vice chair of the Department of Obstetrics, Gynecology & Reproductive Sciences at the University of Pittsburgh; and Dr. Sharee Livingston-Anderson, ob-gyn department chair at UPMC Lititz.This content was originally published on September 26, 2023.

In this episode of Better Edge, Daniela E. Matei, MD, chief of Reproductive Science in Medicine at Northwestern Medicine, discusses her groundbreaking research on chemotherapy-resistant ovarian cancer. She explains how her team discovered the role of cholesterol in cancer cell survival and the innovative use of nanoparticles to block cholesterol uptake, offering new hope for treatment. Dr. Matei also highlights the potential for combining this approach with traditional chemotherapy and immunotherapy to enhance patient outcomes.

Send us a Text Message.In this episode of "Taco Bout Fertility Tuesday," Dr. Mark Amols delves into the groundbreaking world of vitrification—a transformative technique that has revolutionized the field of fertility preservation. Vitrification, or flash freezing, is a process that prevents the formation of ice crystals in cells, ensuring their viability and integrity. This episode unpacks the science behind vitrification, explaining how it differs from traditional slow freezing methods and why it represents a significant advancement in reproductive medicine.Join Dr. Amols as he explores the origins of vitrification, initially developed for preserving tissues, and its subsequent adaptation for freezing eggs, embryos, and stem cells. Learn about the challenges of slow freezing, where the formation of ice crystals could damage cells, and how vitrification overcomes these obstacles with remarkable efficiency.Dr. Amols discusses the profound impact of vitrification on IVF success rates, highlighting how survival rates have soared from 55-65% with slow freezing to over 90% with vitrification. He shares compelling stories from his own practice, demonstrating how this technology has improved outcomes for patients, allowing for more flexible and safer fertility treatments.This episode also covers the broader implications of vitrification beyond human fertility, including its applications in the food industry, animal breeding programs, and the preservation of sensitive drugs and vaccines. Dr. Amols explains how future advancements, such as nanotechnology and magnetic freezing, promise to further enhance cryopreservation techniques.Whether you're a scientist, a student, or someone navigating the complexities of fertility treatment, this episode provides a thorough and engaging look at one of the most significant advancements in reproductive science. Tune in to understand how vitrification is not just preserving cells, but also hopes and dreams for countless individuals and families.If you enjoy this episode, please leave a five-star review and share it with friends who might find the science of fertility fascinating. As always, Dr. Amols looks forward to bringing you more insights on "Taco Bout Fertility Tuesday."Thanks for tuning in to another episode of 'Taco Bout Fertility Tuesday' with Dr. Mark Amols. If you found this episode insightful, please share it with friends and family who might benefit from our discussion. Remember, your feedback is invaluable to us – leave us a review on Apple Podcasts, Spotify, or your preferred listening platform. Stay connected with us for updates and fertility tips – follow us on Facebook. For more resources and information, visit our website at www.NewDirectionFertility.com. Have a question or a topic you'd like us to cover? We'd love to hear from you! Reach out to us at TBFT@NewDirectionFertility.com. Join us next Tuesday for more discussions on fertility, where we blend medical expertise with a touch of humor to make complex topics accessible and engaging. Until then, keep the conversation going and remember: understanding your fertility is a journey we're on together.

Guests include Gina Sanchez to talk about her paper, “Status of abortion curriculum in genetic counseling: Survey of graduate programs and recent graduates in the United States” and Dr. Holly Rankin to discuss her paper, “Termination counseling among US perinatal genetic counselors in the setting of second trimester fetal anomalies.”   Segment 1: Gina Sanchez, MS, MB(ASCP), CGC is a genetic counselor and Instructor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the McGovern Medical School at The University of Texas Health Science Center at Houston. She received a BS in Zoology from Texas Tech University in 2012, a MS in Molecular Pathology from Texas Tech University Health Sciences Center in 2013, and a MS in Genetic Counseling from The University of Texas Genetic Counseling Program in 2022. Gina provides prenatal genetic counseling services in both English and Spanish at several Houston area clinics. She is a member of the National Society of Genetic Counselors and the Texas Society of Genetic Counselors. Gina's research interests include genetic counseling education and increasing access to genetic counseling care for the Spanish-speaking patient population. In this segment, we discuss: Assessment of the abortion curriculum in genetic counseling graduate programs and the study participants. Variability in the amount and types of abortion training across surveyed programs. Factors influencing the training provided. Greater satisfaction and preparedness among graduates from programs with a dedicated abortion curriculum. Notable discrepancies between responses from recent graduates and program representatives. Key topics highlighted as important parts of abortion education. Variability in clinical training as a barrier to abortion education and potential solutions to standardize this education. Segment 2: Dr. Holly Rankin received her undergraduate degree in anthropology, graduating summa cum laude, from the University of California, Los Angeles. She completed her medical education at Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia where she was inducted into the Gold Humanism and the Alpha Omega Alpha Honor Societies. Dr. Rankin completed her residency training in Obstetrics and Gynecology at Johns Hopkins University, Baltimore. She received the Ryan Program Excellence in Family Planning Award at the end of residency training. Dr. Rankin is excited to be a Complex Family Planning fellow at UC Davis and plans to focus her career on providing abortion and contraceptive specialty care to underserved, rural communities. In this segment, we discuss: The impact of state laws and location on counseling and termination options. Differences between genetic counselors and other healthcare providers in handling these cases. Balancing patient autonomy with counseling challenges. How reproductive justice affects the discussion of termination options, especially with changing abortion laws.   Follow us on Instagram @dnadialoguespodcast and on LinkedIn at Journal of Genetic Counseling.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.  

Containing the matter of the Junior Philosopher. Timestamps: introductions, recent non-podcast reads, general discussion of the concept of "the family" (0:00) David H. Keller, MD background, non-spoiler discussion (29:51) plot summary and spoiler discussion (51:41) Bibliography: Hicks, Mar - "Computer Love: Replicating Social Order Through Early Computer Dating Systems" (2016) Lehmann-Haupt, Rachel - "Reconceptions: Modern Relationships, Reproductive Science, and the Unfolding Future of Family" (2023) Moskowitz, Sam - introduction to "Life Everlasting and Other Tales of Science, Fantasy and Horror" (1947)

Season 7 FinaleGretchen Sisson, PhD is a qualitative sociologist who studies abortion and adoption in the United States, based at Advancing New Standards in Reproductive Health (ANSIRH) in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco. She is the author of Relinquished: The Politics of Adoption and the Privilege of American Motherhood, a ten-year examination of adoption relinquishment during the years of Roe.To skip ahead to the interview go to timestamp: 11:36Relinquished: The Politics of Adoption and the Privilege of American Motherhood, by Gretchen SissonLIVE RECORDED PODCAST  with Adoption: The Making of Me (ATMOM) & PHOTO EVENT with JEFF FORNEY of THE INNOCENT PEOPLE PROJECT - September 7th in Kansas City, Missouri.RESOURCES for AdopteesS12F Helping AdopteesGregory Luce and Adoptees Rights LawJoe Soll & other adoptee resourcesFireside Adoptees Facebook GroupReckoning with the Primal Wound DocumentaryHiraeth Hope & HealingMoses FarrowNational Suicide Prevention Lifeline – 1-800-273-8255 OR Dial or Text 988.NAMI Hotline at 1-800-950-NAMI (6264) or email them at info@nami.orgAdoptee Therapist DirectoryIf you want to support our show, visit our Patreon Page.Thank you to our Patreons! Join at the $10 level and be part of our monthly Zoom adoptee community. Our next Zoom is on 7/13 at 1 pm ET.Our Patrons:  Laura, Barbara, Ramona, Linda, Daphne, Denise, Michelle, Emily, Linda, John, Eric, Beth, Ron, Tony, Kristi,  Kristen, Jane, Kelley, Sandra, The Harpy, Kristan, Lisa,  Michelle, Jesper, Julie, Rivi, Robert,  Colleen, Janet, Robin, Lynn, Mikki, Sharon, Carol, Elizabeth, Diane, Ann, Darra, A.M., Kelly, Lyn, Lynn Wood, Jeff, Karla, Ellen,  Gayle Whitlock,  Dave, Kim, Simone, Liesl, Kelly, Sherry, Barbara, Sandra, Darla, Lisa, Karen and Sally.Support the Show.To support the show - Patreon.

Gretchen Sisson, Ph.D. is a qualitative sociologist who studies abortion and adoption in the United States. She is a researcher at Advancing New Standards in Reproductive Health in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco.   Gretchen's studies on adoption include hundreds of in-depth interviews with women who have relinquished infants for domestic adoption over the past sixty years, with a particular focus on women who have relinquished since Roe v. Wade. Her research on adoption decision-making after abortion denial (as part of The Turnaway Study) was cited in the Supreme Court's dissent in Dobbs v. Jackson Women's Healthfrom Justices Breyer, Kagan, and Sotomayor.  In response to the oral arguments and decision in Dobbs, Gretchen authored pieces in the Washington Post and The Nation. In these op-eds, Gretchen condemns the court's decision that adoption over abortion is the best moral alternative and outlines the harsh realities women face when relinquishing a child for adoption. Gretchen has a strong media presence and has been published and quoted in AP News, Atlantic, BBC,Bitch Media, Bloomberg, Christian Science Monitor, Intelligencer, Good Morning America, Ms Magazine, NBC News, Next Question with Katie Couric, Publisher's Weekly, Refinerhttps://www.pulledbytheroot.com/

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog There is a lot of New Medical Information that is important for patients to make healthy decisions about their care or the care of their loved ones that you won't hear about on the news. For new research to reach you, the public, a researcher or a drug company has to spend a great deal of money for the public relations people to push information into the light.  I compiled the research I thought you might want to know about that has been discovered during the past 6 months. I always use these studies to educate my patients and to change my protocols for treatment, although many of them have been part of my practice for quite a while, because they just confirm what I have been seeing in my Integrative and preventive medical practice for years. The First Group of Discoveries Relate to Menopause,  and the Risks of Being Menopausal The most recent article in Lancet confirmed what has been obvious to me in my GYN practice for years. I am not sure why this actually required a study to prove that Menopause is tied to a higher rate of depression and anxiety, in conjunction with insomnia, higher stress perception, and hot flashes.  This study documented what the loss of estradiol, progesterone and testosterone can do to women in menopause.  The sad fact is that this article doesn't tell the reader what they need to know, how to treat these symptoms. However, I will let you in on a self-discovered fact:  The replacement of the hormones that disappear before and during menopause can be replaced in a non-oral delivery system to treat these symptoms.  I have 40 years of medical practice that proves my findings that agree with the problem, and my treatment with hormones. The Lancet: Menopause tied to mental health issues in certain women A study found that when certain women are menopausal, they increase their risk of Depression, anxiety, bipolar disorder who experienced stressful life events, had poor sleep related to hot flashes, or had previous depressive symptoms of depression were more likely to develop menopause-related mental health problems. Researchers wrote in the journal The Lancet that some women escape the mental health effects of menopause altogether. HealthDay News (3/6) Another recent study about menopause discovers that a lack of estradiol in the post menopause causes women to have trouble thinking. I agree with that revelation, but why doesn't the research take the next step and suggest a treatment to prevent this result of hormone loss?  Why doesn't the research tell us how to help women think by replacing their estradiol? Many other studies confirm that replacing estradiol will delay the onset of dementia by 10 years.  Another study reveals that the replacement of testosterone will delay dementia it 10 more years. These studies occurred over 20 years ago, but this study doesn't cite them. Poor and worsening cognitive function is one of the most frequent complaints of my new patients coming to BioBalance Health® for treatment of menopause and low testosterone with bioidentical hormone pellets. Dr Maupin: I am continually reminded of the importance of testosterone and estradiol replacement is to aging men and women when they come back for their second pellet insertion and review their list of the symptoms they complained of before they started E and T pellets The most frequent response I witness when I ask if a woman's ability to think, do her job and stay organized is completely better after 3 months of Estradiol and Testosterone pellets, is crying with relief!   Many patients are deeply worried that they are developing dementia, specifically Alzheimer's Disease when they first come to me, but are able to go back to work and or experience a renewed quality of life because their ability to think, they can now feel confident in their professions and careers. Dr M Estradiol associations with brain functional connectivity in postmenopausal women Testo, Abigail A. BS1; Makarewicz, Jenna BS1; McGee, Elizabeth MD2; Dumas, Julie A. PhD1 Author Information From the 1Department of Psychiatry 2Department of Obstetrics, Gynecology, and Reproductive Sciences, Larner College of Medicine, University of Vermont, Burlington, VT.  The results illustrate the relationship between estradiol level and functional connectivity in postmenopausal women. They have implications for understanding how the functioning of the brain changes for individuals after menopause that may eventually lead to changes in cognition and behavior in older ages. © 2024 by The Menopause Society I have another problem with studies that should be shared with patients is that they often imply that menopausal women are “crazy” instead of saying that women after menopause develop mental health issues that can be treated with hormone replacement. Women who are menopausal are not mentally ill they are hormone deprived! I view this as a “slam” and divisive attack on aging women. The fact that if we gave women what they need …hormonal replacement ….they would not suffer the symptoms of mental health disorders. Menopause tied to mental health issues in some women A study found that women who experienced stressful life events, who had poor sleep due to nighttime hot flashes, or who had previous depressive symptoms or depression were more likely to have menopause-related mental health problems. Researchers wrote in the journal The Lancet that some women escape the mental health effects of menopause altogether. Full Story: HealthDay News (3/6) The Second Group of Articles Is About The Loss Of Estrogen In Menopause Causes Heart Failure and Atrial Fibrillation.  This article from the European Society of Cardiology reveals that the longer women live without estrogen (e.g. is menopausal), the higher risk of developing heart failure and atrial fibrillation. Once again, there is no mention about how to prevent this disease!  Why can't they study the women who replaced their hormones and compare them to the women who didn't?                             Hormone Therapy May Boost Weight Loss for Postmenopausal Women Who are Overweight or Obese On Semaglutide, Study Finds My practice BioBalance Health® has a weight loss program that is very effective for weight loss using Semaglutides, and terzipatide.  For women who are menopausal we have found that they lose weight much more quickly if they are on E2 and T pellet hormone replacement.  This research article confirms the findings of this study. If you are menopausal and have gained weight after menopause that is hormonal and the faster, you can get on non-oral estradiol and testosterone replacement then you will be more likely to get to your ideal weight! March 18, 2024 Hormone therapy may boost weight loss for postmenopausal women on Semaglutides. Healio (3/18, Welsh) reports, “Hormone therapy was associated with an improved weight-loss response for postmenopausal women with overweight or obesity treated with Semaglutides, according to cohort study results published in Menopause.” In the study, “postmenopausal women on hormone therapy had a higher percentage of total body weight loss at 3 (7% vs. 5%; P = .01), 6 (13% vs. 9%; P = .01), 9 (15% vs. 10%; P = .02) and 12 (16% vs. 12%; P = .04) months of semaglutide treatment compared with no hormone therapy.” How and Why to Treat Metabolic Syndrome  Metabolic Syndrome is a combination of hypertension, high lipids, insulin resistance, obesity, prediabetes or diabetes, large abdominal measurement.  This combination puts patients at risk for heart disease and early death.  Many conditions and outcomes have been associated with metabolic syndrome, but now we have a treatment that can prevent one of the outcomes of this syndrome, the generic drug Metformin ER. Metformin, Cognitive Function, and Changes in the Gut Microbiome Endocrine Reviews, Volume 45, Issue 2, April 2024, Pages 210–226, Published: 21 August 2023 Article history Abstract The decline in cognitive function and the prevalence of neurodegenerative disorders are among the most serious threats to health in old age. Metformin can preserve cognitive function by treating metabolic syndrome and improving the gut biome that produces neurotransmitters. I am not naive enough to believe that the only thing that your brain needs to perform well is two sex hormones (E2 and T).  This new research from the Endocrine Society describes how the generic, inexpensive medication Metformin ER, can help preserve an aging patient's ability to think.  That is primarily because the brain has insulin receptors, and when a patient has insulin resistance brain cells don't receive enough blood-sugar to be able to think!  By taking metformin ER (extended release) plus replacing estradiol plus testosterone in pellet form, the brain gets what it needs (blood sugar) and patients can think again! The second factor the researchers found to be important to brain health and problem solving, is healthy gut bacteria in the intestines.  This requires eating whole foods, especially fruits and vegetables every day, and not eating fast food, alcohol, simple sugars, and preservatives that kill good bacteria. We recommend a daily probiotic by Mega + the lifestyle changes above. If you want to keep your ability to think for your whole life then you need E2 and T in pellet form if you are a woman and T if you are an aging male, plus Metformin ER daily and the above lifestyle changes. Metabolic Syndrome, Obesity, is the Biggest Risk for Cancer Metabolic syndrome may increase cancer risk by 30% People with metabolic syndrome had a 30% higher chance of developing cancer over the course of a decade after diagnosis, according to a study published in the journal Cancer. The researchers also studied inflammation by tracking C-reactive protein, concluding that elevated levels of the protein along with metabolic syndrome were “significantly associated with subsequent breast, endometrial, colorectal and liver cancers.” Full Story: National Public Radio (3/11) The struggle to stay young and healthy is a difficult fight but the most important battle that you will wage as an adult.  If people knew the whole truth, would they stop overeating, drinking, smoking, avoiding exercise, or stop taking illicit drugs?  I can only hope that if we convince people to take care of themselves better and replace the hormones that are missing as soon as they are clinically deficient, then they will also listen to the truth about the various ways to support their health and prevent disease.  I also hope that the doctors who write articles and do research stop treating women like crazy people instead of the gender that actually runs the world and not only nurtures the children but also organizes homes and businesses.  We are NOT crazy when we need hormones to be replaced (PMS, MENOPAUSE), we are experiencing symptoms of hormone-deprivation, and we just need to be treated with the hormones that are missing!

While it may seem that menopause has begun to become more open to talking about, there is still a stigma and the idea that women should deal with the symptoms that come with it, including having issues with orgasms. Well, Dr. Lauren Streicher is on a mission to change that. Dr. Streicher is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, a certified menopause practitioner of The Menopause Society, and the founding Medical Director of the Northwestern Medicine Center for Sexual Medicine and Menopause.In addition to her academic appointment at the Feinberg School of Medicine, Dr. Streicher is on the faculty of Northwestern University's Graduate Program in Reproductive Science and Medicine for students pursuing a Master of Science degree in medical research.She is a best-selling author and has written multiple books including The Essential Guide to Hysterectomy and Sex Rx: Hormones, Health, and Your Best Sex Ever. Inside Information, a series of books about menopause launched in 2021 and includes Slip Sliding Away: Turning Back the Clock on Your Vagina and Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat. Her next book, Put the O Back into Mojo: A Post-Menopause Guide to Orgasm, is scheduled to be released in 2024. We discussed the critical importance of addressing hormone-related issues that impact mental health and sexual function in women. Topics ranged from the concept of "drug holidays" to the potential benefits of Viagra for conditions like sexual dysfunction, SSRI use for menopause management. Dr. Streicher provided invaluable insights into managing these challenges.We also talked about societal taboos surrounding sexuality and the lack of emphasis on pleasure in sex education. Dr. Streicher shared insights from her collaboration with her daughter, Rachel, on their groundbreaking book about orgasms and libido. This book combines medical and psychosocial perspectives to educate and empower women on these crucial aspects of sexual health.Highlights-Importance of hormones in sexual healthImpact of hormone imbalances on sexual function, Hormone replacement therapy for managing sexual dysfunction.Addressing Misconceptions about Hormone Replacement TherapyCommon misconceptions about hormone replacement therapy,Benefits and risks associated with hormone replacement therapy,Importance of informed decision-making in hormone therapyGaslighting and Lack of Education in Sexual HealthLack of education and information on sexual health.Challenges in accessing comprehensive sexual health education.Addressing misinformation and stigma related to sexual health.Menopause and Sexual DysfunctionImpact of menopause on sexual function. Common sexual health issues during menopause.Treatment options for sexual...

Listen as Dr. Zoe Rodriguez shares her medical and patient-advocating expertise about life before and after hysterectomy.Episode SummaryJoin Fempower Health as we discuss hysterectomies with Dr. Zoe Rodriguez, the Assistant Professor of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai. In this episode, we address the misconceptions, diverse cultural perspectives, and crucial insights surrounding hysterectomies. We talk about different hysterectomy options, recovery expectations, and the significant impact of surgical choices on women's health. Whether you are considering this procedure or seeking deeper understanding, this discussion offers valuable guidance to navigate your health decisions confidently.Key TakeawaysThe different types of hysterectomy surgery—including total, supracervical, and partial hysterectomy—and why it's so important to know the different options.How cultural backgrounds influence perceptions of healthcare and surgical decisions, particularly within the Latina community.The importance of setting realistic expectations and being well-informed about post-surgical recovery, hormonal impacts, and sexuality after hysterectomy.Debunking common misconceptions that Western physicians are “eager to perform surgeries,” plus ethical considerations and patient-centric approaches adopted by modern medicine.Minimally invasive procedures for fibroids and other conditions that can be alternatives to hysterectomy.The role of informed consent and ensuring patients are fully aware of what their surgery entails, including the potential removal of ovaries and subsequent hormonal implications.Tips for patients on how to interact effectively with healthcare providers to ensure all their concerns are addressed.Dr. Rodriguez's vision for accessible, high-quality healthcare for all, regardless of immigration or citizenship status.Quote“I need you to really pay attention to your symptoms because that's the only way I'm gonna know. And if you are having symptoms, then I can provide you with these beautiful menopausal hormone therapies.”- Dr Zoe RodriguezRelated to this episode:Resources on Pelvic Health and Peri/MenopauseLearn about ACOG (American College of Obstetricians and Gynecologists): A leading organization in women's health care, providing guidelines and practice bulletins for medical practitioners.Learn about The Menopause Society: Likely referring to The North American Menopause Society (NAMS), which provides guidance and information on menopause management.Learn about ASRM (American Society for Reproductive Medicine): An organization dedicated to advancing knowledge and expertise in reproductive medicine, including fertility preservation.If you're passionate about advancing women's health, there are many ways you can support the Fempower Health Podcast. Here's how:Subscribe and Listen: Tune in to new episodes every Tuesday by subscribing to the Fempower Health Podcast on iTunes or

In today's episode, award-winning journalist, Rachel Lehmann-Haupt shares insights from her two books, which have ignited the knowledge and passion that came from her own family building journey.  Her latest book, Reconceptions: Modern Relationships, Reproductive Science, and the Unfolding Future of Family, calls upon her experience of becoming a single parent by choice. She dives into her own family building journey, how she's navigated using a sperm donor and the relationships she's built from this, and how she's rethinking and redefining the meaning of family.   Guest: Rachel Lehmann-Haupt, award-winning journalist and author  Host: Dan Bulger, Progyny    For more information, visit Progyny's Podcast page and Progyny's Education page for more resources. Be sure to follow us on Instagram, @ThisisInfertilityPodcast and use the #ThisisInfertility. Have a question, comment, or want to share your story? Email us at thisisinfertility@progyny.com.    

If you're navigating or considering undergoing fertility treatments like IVF, and are confused by all the tests and information out there, you are not alone. Sometimes in this process, we feel like we are given too much information and not enough information at the same time! This podcast episode, in honor of National Infertility Awareness Week (NIAW) 2024, is a spotlight on why we should advocate for our reproductive health and know our options.Dr. Vrunda B. Desai, FACOG, the VP of Medical and Clinical Affairs at CooperSurgical, joins Andrea in studio to share how CooperSurgical is accelerating what's possible to help people build their families sooner, and how tests like PGT-A, PGT-M, and PGTai can revolutionize the embryo selection process. She is a Physician, Researcher, Educator and Medical Affairs leader at CooperSurgical and is a Board-Certified Ob/Gyn with fellowship training in Minimally Invasive Gynecological Surgery. Dr. Desai is also an Adjunct Assistant Professor in Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. She's seen first hand how many options current fertility treatment patients have when trying to build or expand their families.This episode also features back Sydney Sharon, Social Media and Community Manager at California Cryobank by CooperSurgical, who shares how she and her wife Brit chose their sperm donor and why representation matters when we talk about infertility and modern family building. Thanks to episode sponsor CooperSurgical – a fertility and women's health company, that puts time on the side of women, babies and families at the moments that matter most – for supporting this conversation. For more, visit coopersurgical.com Hosted on Acast. See acast.com/privacy for more information.

Today we're talking with Gretchen Sisson, a research sociologist with Advancing New Standards in Reproductive Health (ANSIRH) in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco. She is the author of Relinquished: The Politics of Adoption and the Privilege of American Motherhood, a critical, ten-year examination of domestic adoption. Centering on the stories of relinquishing mothers, the book chronicles America's refusal to care for families at the most basic level, and instead allows cultural and political ideas of adoption to advance an individual, private solution to large-scale social problems. In our conversation, we discuss the function of adoption in society, its representation in popular culture, and the experiences of birth mothers. We explore the stereotypes and tropes perpetuated by modern adoption stories in TV and film like in shows like This is Us and 16 and Pregnant, and the impact of these narratives on societal biases and policies. We also talk about how the women who Gretchen spoke with feel like The Handmaid's Tale is the closest representation of their experience of relinquishing their child. We then delve into the complexities of adoption, the historical context of pre-Roe adoption, and the consequences for birth mothers and relinquished children. This discussion explores the complexities of adoption, highlighting the experiences and perspectives of birth mothers as captured in Gretchen Sisson's new book. It delves into the emotional journey of birth mothers, their hopes and expectations, as well as the challenges and grief they face. The conversation also touches on the impact of adoption on adoptees, particularly in terms of trauma and identity. It further discusses the connection between adoption and reproductive justice, and the need to critically examine the narratives and beliefs surrounding adoption. Our discussion concludes with a discussion on the potential of pop culture to shape a more nuanced and inclusive narrative around adoption. Here is a link to find out more about Gretchen's book: https://www.relinquishedbook.com/ DOWNLOAD THE TRANSCRIPT: https://braaainspodcast.com/s/Braaains-Podcast-EP048-transcript-The-Handmaids-Tale-This-is-Us-and-Adoption.pdf Contact us: BraaainsPodcast.com Follow: @BraaainsPodcast Music: @_Deppisch_ Support this show: Patreon.com/BraaainsPodcast

Hello and welcome to A Bit Of A Boost with me, George Anderson   I'm a wellbeing and performance coach, speaker and author and this podcast brings together guest experts, inspirational stories and ideas that I hope will you a bit of a boost.   I came across some research recently about the impact of open water swimming on menopause symptoms, and was delighted when the study author Professor Joyce Harper accepted my invitation to join me on the podcast to discuss it.   Having had an overwhelmingly positive response to a previous episode on menopause with Catherine O'Keeffe I know this is a topic that many of you are interested in so I was excited to get into the topic again.   Joyce Harper is an award winning Professor of Reproductive Science at the Institute for Women's Health, University College London.   She has worked in the fields of fertility, genetics, reproductive health and women's health for over 30 years, is author of the book ‘Your Fertile Years' and host of the ‘Why didn't anyone tell me this?' podcast.   You can find out more about Joyce and her work at joyceharper.com   Purchase a copy of Your Fertile Years on Amazon here: https://www.amazon.co.uk/dp/152935627X   Listen to Why Didn't Anyone Tell Me This on Spotify: https://open.spotify.com/show/0Etr1ygKlT7aLgrW4B0fyg   Link to research and Joyce Harper's academic profile: https://www.ucl.ac.uk/news/2024/jan/cold-water-swimming-improves-menopause-symptoms

https://www.compregen.com/ Listen to us live on mytuner-radio, onlineradiobox, fmradiofree.com and streema.com (the simpleradio app)https://onlineradiobox.com/search?cs=us.pbnnetwork1&q=podcast%20business%20news%20network&c=ushttps://mytuner-radio.com/search/?q=business+news+networkhttps://www.fmradiofree.com/search?q=professional+podcast+networkhttps://streema.com/radios/search/?q=podcast+business+news+network

About the Lecture: Understanding reproductive health is key for everyone, whether we want children or not. Since writing a book called Your Fertile Years, Professor Harper has been researching into all aspects of reproductive health education and heads the International Reproductive Health Education Collaboration who aim to deliver reproductive health education to everyone. She created a survey to ask teenagers around the world their attitudes and knowledge to reproductive health. So far data has been obtained from the UK, Belgium, Greece and Japan. And she asked UK teenage girls how they feel about having a period. She has also surveyed over 6000 women to ask their attitudes and knowledge of their periods and menopause. Through this research, resources have been created to help teachers and health professionals provide education and she is heading the development of the UK Menopause Education and Support programme, so that all women in the UK can understand what happens during menopause. About the Speaker Joyce Harper, Professor of Reproductive Science at UCL Joyce Harper is an award-winning educator, author, podcaster, academic, and scientist. She is Professor of Reproductive Science at University College London in the Institute for Women's Health where she is Head of the Reproductive Science and Society Group. She has worked in the fields of fertility, genetics and reproductive science since 1987, written over 240 scientific papers and published three books. She is leading the development of a UK Menopause Education and Support Programme with support from key organizations. She is co-founder of the UK Fertility Education Initiative (www.fertilityed.uk) and founder of the International Reproductive Health Education Collaboration (www.eshre.eu/IRHEC). She is working with schools in the UK and globally to help deliver reproductive health education. Her latest book, Your Fertile Years, What you need to know to make informed choices, was published in 2021 by Sheldon Press. Her podcast is called Why Didn't Anyone Tell Me This? Is available on all podcast channels. Further information – www.joyceharper.com Follow on X (formerly Twitter), Instagram, Tiktok and Linkedin - @ProfJoyceHarper

Millions of women around the world experience the menopause each year; it's an important milestone, which marks the end of their reproductive years.But every individual's experience of it is personal and unique. In some cultures, there's a stigma about this life stage – it's viewed with trepidation and as something to be dreaded. In other cultures, it's considered to be a fresh start - a time of greater freedom when women no longer have to worry about their menstrual cycles.In this edition, recorded at Northern Ireland Science Festival in Belfast, Claudia Hammond and her expert panel take a global look at the science of the menopause and debunk some myths along the way.As Claudia and her guests navigate their way through the menopause maze, they look at the most recent academic research in this area. They also discuss the physical and psychological symptoms, the lifestyle changes women can make and the different treatments available, including Hormone Replacement Therapy.Claudia also speaks to the American biological anthropologist who has dedicated an impressive 35 years of her life to studying the average age of the menopause in different countries - and finds out how hot flushes vary in different cultures. She also speaks to a doctor who is working hard to make women's health less of a taboo subject in the community where she works. And she hears from a Professor of Reproductive Science who is setting up the UK's first menopause school.Producer: Sarah Parfitt Co-ordinator: Siobhan Maguire Editor: Holly Squire Sound engineers: Andrew Saunderson and Bill Maul Mix engineer: Bob NettlesImage used with permission of the Northern Ireland Science Festival

Dr. Amander Clark is the President of the International Society for Stem Cell Research (ISSCR) and Founding Director of the Center for Reproductive Science, Health, and Education at the University of California, Los Angeles. Dr. Agnete Kirkeby is a Program Chair of the ISSCR Annual Meeting, Associate Professor at Lund University and the University of Copenhagen, and Group Leader at the Novo Nordisk Foundation Center for Stem Cell Biology – reNEW. Dr. Malin Parmar is a Program Chair of the ISSCR Annual Meeting, Professor at Lund University, and a New York Stem Cell Foundation – Robertson Investigator. They talk about the upcoming ISSCR 2024 meeting in Hamburg, Germany from July 10-13, 2024. They discuss the meeting's clinical focus, spotlight and plenary sessions, and opportunities for students and postdocs.

We like to think of adoption as an unmitigated social good – a practice that UCSF sociologist Gretchen Sisson says “makes possible the maintenance of both the heteronormative family ideal beloved by the right and the nontraditional, chosen family ideals embraced by the left.” But Sisson says that framing ignores the experiences of birth mothers, who tend to have far less socioeconomic power than adoptive parents and who bear the complicated and even traumatic consequences of relinquishing an infant. Sisson conducted more than 100 interviews with birth mothers who relinquished their children to learn how they came to decide on adoption and the impact that decision has had on them and their families. Her new book is “Relinquished: The Politics of Adoption and the Privilege of American Motherhood.” Guests: Gretchen Sisson, qualitative sociologist studying abortion and adoption at Advancing New Standards in Reproductive Health (ANSIRH) in the Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF; author, "Relinquished: The Politics of Adoption and the Privilege of American Motherhood” - her research was cited in the Supreme Court's dissent in Dobbs v. Jackson Women's Health Organization. Serina Chacon, birth mother based in Northern California

In this episode of the podcast I chat to Professor Joyce Harper - an award-winning educator, author, podcaster, academic, and scientist. She is Professor of Reproductive Science at University College London in the Institute for Women's Health where she is Head of the Reproductive Science and Society Group. I'm very grateful that Joyce agreed to come and chat to me about her work leading the development of a UK Menopause Education and Support Programme. Joyce and her team are already well into the discovery phase of researching what the programme should include - and here's the fun part - if you're listening to this close to the release date in 2024, you can participate in their research by completing this survey: https://ifwh.eu.qualtrics.com/jfe/form/SV_8CVKG2I1RZzHGXI or by joining one of the focus groups: https://www.ucl.ac.uk/global-health/uk-national-menopause-education-and-support-programme    The team is very keen to get feedback and input from as broad a range of participants as possible - so if you have things to say, please get in touch with them!  We also talk about Joyce's podcast - Why Didn't Anyone Tell Me This? - and her love of cold water swimming - she's even co-authored a scientific paper all about the impact of cold water swimming on menstrual and perimenopausal symptoms: https://pubmed.ncbi.nlm.nih.gov/38271095/ (free to read) You can also find her at www.joyceharper.com and follow her on Twitter, Instagram, Tiktok and Linkedin https://joyceharper.com/podcasts/ You can also find us over on Instagram https://www.instagram.com/middlingalong_podcast/ and you can listen to past episodes at https://middlingalong.com     Join our newsletter, The Messy Middle, for fortnightly goodness into your Inbox: https://dashboard.mailerlite.com/forms/323784/90772270045202190/share    We're delighted to be listed as one of the Top 25 podcasts for midlife and menopause here: https://www.lattelounge.co.uk/podcasts-about-the-menopause/   It would mean so much if you'd subscribe, rate, and review us to share the love and help others find the podcast too!  You can also find me at https://www.instagram.com/managingthemenopause  or at www.managingthemenopause.com where we offer 1-1 coaching and workplace training.  Get our free 'Guide to your GP appointment' at https://www.managingthemenopause.com/free-resources 

Scientists at Yale think freezing ovarian tissue at a young age could help us to postpone or event prevent the onset of menopause altogether. Jonathan speaks to Dr Kutluk Oktay, Professor of Obstetrics, Gynecology and Reproductive Sciences, and Director of the Laboratory of Fertility Preservation and Molecular Reproductive Biology at the Yale School of Medicine.

It's been referred to as puberty in reverse but what actually is the perimenopause? How do you know if you're in it? What can you do to soften the symptoms and what can men do to help those they care about going through it? Inside Health is talking about the peri-menopossibilities and learning why it's not as bad as you've been led to believe. Endocrinologist Professor Annice Mukherjee and Professor in Reproductive Science at University College London Joyce Harper are alongside Inside Health's resident GP Margaret McCartney and presenter Laura Foster. They're answering your questions to help demystify the perimenopause.Presenter: Laura Foster Producer: Tom Bonnett

If you're dreading the upcoming holidays, with their awkward conversations and cringe-worthy personal questions, this episode is for you! We are joined by returning guest, Dr. Georgia Witkin to discuss some handy tips and tricks for surviving the holiday season ahead. Dr. Witkin is the Director of Psychological Services and Wellness at RMA of New York and an assistant professor in the Department of Obstetrics, Gynecology, and Reproductive Science at Mount Sinai Medical Center. Tuning in today, you'll hear Dr. Witkin's thoughts on why you need to stop “should-ing” and her insights for being discerning about what and with whom you share. She also highlights possible answers you can give to relatives asking questions or making uncomfortable statements about your fertility. Press play to hear these and other helpful suggestions, including the option to opt out this holiday season, and remember: base your expectations on reality and not wishful thinking. Thanks for listening and happy holidays! 

Endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus, causing pain and affecting fertility. It is estimated to cost the UK economy £8.2bn a year in treatment, loss of work and healthcare costs. Up to 30% of women who have surgery for endometriosis experience a recurrence within five years, according to the National Institutes of Health. There is still no cure for the condition. On the Sky News Daily, host Sally Lockwood is joined by Charline Bou Mansour, a Sky News reporter who has endometriosis, and Andrew Horne, Professor of Gynaecology and Reproductive Sciences at Edinburgh University, to explore the search for a way to relieve, or even cure, endometriosis. Producers: Emma Rae Woodhouse, Alex Edden and Soila ApparicioPromotions Producer: Jada-Kai Meosa John Editor: Wendy Parker

In this "Podcast Takeover," Dr. Lidia Schapira guest hosts to discuss with Dr. Shannon Westin her own JCO paper, which reports on the DUO-E Trial. Dr. Ramez Eskander also joins in this lively discussion. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth on manuscripts published in the Journal of Clinical Oncology. I am your host, Shannon Westin, Social Media Editor of the JCO and Gynecologic Oncologist by trade. And actually, I'm super excited today because we are going to have a podcast takeover because we are discussing my own work, which was simultaneously presented at the European Society of Medical Oncology 2023 Congress and published in the Journal of Clinical Oncology on October 21st, 2023. And this was the DUO-E trial, “Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer.” Because we're discussing this work and we wanted you to have an unbiased podcast discussion, Dr. Lidia Schapira, who is a Professor of Medical Oncology at Stanford University and an Associate Editor of JCO and the Art of Oncology podcast host, is going to take over this podcast and really just pepper me with questions about this exciting work.  Welcome, Dr. Schapira.  Dr. Lidia Schapira: Thank you so much. It's such a pleasure to be with you. Dr. Shannon Westin: And before I turn over the reins, I also want to introduce one of my colleagues, who's going to be providing quite a bit of insight on this topic, Dr. Ramez Eskander, who is Professor of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Diego. And you will know he's the principal investigator of the GY-018 study, which established pembrolizumab and chemotherapy as the new standard of care in endometrial cancer. Welcome, Ramez.  Dr. Ramez Eskander: Thank you. Thank you, Dr. Westin. It's a pleasure to be here. And congratulations again to you and your study team for this exceptional work.  Dr. Shannon Westin: Thank you. And congratulations to you.  Dr. Schapira, thank you for being here and please do take it away. Dr. Lidia Schapira: So let's start by having you tell us a little bit about the standard of care for women with endometrial cancer and advanced endometrial cancer prior to this study. Ramez, I'm going to direct this question to you first. Dr. Ramez Eskander: For many years, actually since about 2012, carboplatin and paclitaxel, which ironically is a chemotherapy backbone really across all of our gynecologic tumors, emerged as the preferred doublet chemotherapy regimen for the management of advanced-stage metastatic or recurrent endometrial cancer. It evolved through a series of different clinical trials, in fact taking us from whole abdominal radiation, systemic chemotherapy, comparing single agents to doublets and then triplet regimen of TAP to carboplatin and paclitaxel, which ultimately, then, following the presentation of GOG Protocol 209 and its publication, as the chemotherapy backbone, being carboplatin and paclitaxel. And it's been that way for many, many years. Dr. Lidia Schapira: And how effective is the regimen? Dr. Ramez Eskander: The response rates to carboplatin and paclitaxel are actually quite reasonable in the patients who have advanced-stage disease, particularly if they haven't had prior systemic chemotherapy. Response rates in the 50% to 60% range. The issue is that the responses tend to be limited and disease recurrence is an expectation in these patients who have advanced-stage disease. And so that really highlighted the importance of trying to continue to advance therapeutic opportunities in these patients to improve long-term outcomes.  Dr. Lidia Schapira: As we think about improved long-term outcomes, we're thinking about a better treatment and also a kinder treatment, perhaps one that is also less toxic. Can you talk a little bit about the population of women with endometrial cancer? Are these older women? Do they have comorbidities?  Dr. Ramez Eskander: What we're seeing is, interestingly, there has been an evolution a bit in this space. Historically, we used to think about endometrial cancer as—the phrases we used to use are type I and type II. These type I tumors, we would say, are estrogen-driven malignancies; they tend to be seen in overweight or obese patients. And we would identify them in a theoretically younger patient population. And then we had these type II, or what we termed estrogen-independent malignancies, that we would see in an older patient population. Of course, with obesity came metabolic syndrome and other cardiovascular comorbidities, etc. But really, that narrative has evolved dramatically, and that's really something that will be highlighted in, I think, our discussion of these studies today, where the nomenclature that we used to historically use has evolved because of our understanding of the molecular characterization of this disease. So we've really gone away from that, and now we understand that we're seeing all of these different heterogeneous endometrial cancer types amongst patients of different ages, different comorbidities, different races and ethnicities. And so it's created a more complex picture for us. But certainly, there are comorbidities that these patients face, and that's important as we look to identify treatments strategies that are both effective and tolerable. Dr. Lidia Schapira: My final question before we jump into this very exciting study is about the Cancer Genome Atlas work. Can you tell us how that's changed the thinking and the design of the studies? Dr. Ramez Eskander: It was a seminal publication, really, back in 2012/2013 looking at an assessment of endometrial cancers to try and determine whether or not all of these "endometrial cancers" that we used to enroll on a single study are similar or divergent. And it's important because the study I referenced that really established the standard of care, GOG Protocol 209, as carboplatin and paclitaxel, there was no real consideration of molecular characterization at all. We enrolled all patients onto this study without thinking about these variables, of course, because it was designed, conducted, and completed before the TCGA data emerged. But what we learned from the TCGA is there appeared to be four distinct molecular subgroups. There were the POLE-mutated patient population. There was the mismatch repair deficient or MSI-high endometrial cancer population. There was the copy number-high or what we say are the p53-mutated. And then the last cohort was called the NSMP (no specific molecular profile). But now, that's even evolved; some people term it TP53 wild type. That's a bit of even a heterogeneous cohort amongst itself. So we're going to take these subsets, independent of POLE and an MSI-high, and we're going to look at TP53 or copy number-high, and that will probably be divvied out further, and the NSMP, and that will probably be subdivided. But really, it gave us these four components, which has then evolved. Many of you may have heard of the ProMisE algorithm or ProMisE Plus, which looked to take the data from TCGA so that we can start to really look at it in clinical practice. So it's really revolutionized how we think about these patients, how we think about the disease, and how we design trials.    Dr. Shannon Westin: And I just want to add to that because I think that it's so important, what Ramez said about the way we were developing trials, the way we were designing trials. We knew that these classifiers—we were learning these classifiers are prognostic. Now what we're really trying to hone in on is how predictive they are. And certainly, one of the major classifiers that we're going to talking about today is mismatch repair status, and that is most definitely predictive of response to therapies. But we're still learning about the other classifiers and how we might adjust the way we treat people, even deescalating care for certain patients. That is still being proven in clinical trials, although we suspect that it's going to be borne out as other clinical trials report. Dr. Lidia Schapira: It's a perfect segue to this current trial. Tell us a little bit about the objectives and the design of DUO-E. Dr. Shannon Westin: As Ramez said, the standard of care was chemotherapy. And so we wanted to see if there was a way to improve outcomes for these women with advanced and recurrent endometrial cancer in a really clinically relevant, meaningful fashion for patients. And so we knew that this TCGA classifier, the mismatch repair, was so important, and we thought that the addition of immunotherapy to chemotherapy would most certainly work in that population but could even work in the entire population because, generally, endometrial cancer seems to be a little bit more responsive to immunotherapy and to activation of the immune system than, say, some of our other gynecologic malignancies. And so we set out to see what the addition of durvalumab, which is a PDL-1 inhibitor, would add to chemotherapy. And this was two chemo as well as followed by durvalumab maintenance.  But even further, we had some really kind of exciting science data from our lab that said that if we combined a PARP inhibitor with immunotherapy that we could accentuate on the response to therapy and we could get more benefit. And there's kind of a lot behind that, but essentially, what we thought was that the damage that's caused by the PARP inhibitors would create an activation of different immuno-pathways, like STING pathway and activating cytokine release, and that we would get this synergistic activity. So one of the other objectives was to see if the addition of the olaparib, the PARP inhibitor, to durvalumab in that maintenance setting could even further improve benefit. So we had a dual primary endpoint looking at progression-free survival, so the amount of time people live without their cancer coming back. And that endpoint was first, the durvalumab-alone arm to control, and then the second portion of that was the durvalumab/olaparib arm back to control. Dr. Lidia Schapira: So before you tell us about the results, tell us a little bit about the study itself. I mean, I was very impressed that you did it in so many different locations. Tell us about that effort.  Dr. Shannon Westin: This was a huge collaborative effort both with the GOG Foundation, the Gynecologic Oncology Group Foundation, as well as ENGOT, which is our European colleagues that do amazing clinical trials. But in addition to that, we really worked very closely with our industry partner to really make sure we spanned the globe. And so we had groups from all over the world that participated and really were exceptional. The care that was taken and the hard work that went into this type of study across the world really can't be overstated. We were very lucky to have a wonderful infrastructure group. We met weekly for a long time, just keeping an eye on the data and making sure that everything was as positive as possible and, of course, that we were watching the outcomes of the patients very closely and making sure that there was no evidence of harm or issue. And so it really did take a village, truly, to run this study and to ensure that at the end of it, we got really great data that we can trust. Dr. Lidia Schapira: So tell us the results. Dr. Shannon Westin: So DUO-E was positive for both of its primary endpoints, which was very thrilling. So for the first analysis, which is the durva-alone arm to control, we saw a reduction in the risk of progression of 29%, so a hazard ratio of 0.71. And then the addition of olaparib seemed to further enhance this benefit, so a 45% reduction in the risk of progression for a hazard ratio of 0.55. But what's really exciting is our follow-up time was pretty long; it was about 17 months, so we were able to look at a couple of different analyses, including an 18-month landmark analysis where we saw approximately 50% of the patients were still alive progression free at 18 months, as compared to only 21% of patients being alive progression free in the control arm. So there was a doubling in that progression-free survival time point at 18 months, which is thrilling. Dr. Lidia Schapira: So Ramez, as an expert in the field, what was your reaction when you read or heard these results?  Dr. Ramez Eskander: It's exciting, honestly. So we have gone a long time without seeing really significant successes in the endometrial cancer space, a testament to the fact that we hadn't yet developed our understanding of how we could move this needle forward. But Dr. Westin and the DUO-E team conducted an exceptional clinical trial, as you mentioned, international study, rational and important hypothesis to adjudicate. And what we saw here was both now we had other studies—the RUBY trial, the GY018 trial, the  AtTEnd—and now here DUO-E, which added this hypothesis of PARP maintenance in addition to checkpoint to try to augment response and consistent, really provocative data, exciting, in line with what we've seen and hopefully will continue to drive the science in this space, most importantly. Dr. Lidia Schapira: So let me ask you a follow-up question to that. What kind of scientific questions are in the air now as a result of this trial and what the trial found? Dr. Ramez Eskander: Oh, goodness. Shannon and I could both take this, I'm sure. But I think in the dMMR population, we recognize that there's a ton of data that is supportive of the fact that these tumors are immune responsive, particularly in dMMR endometrial cancer, whether it's an epigenetic promoter hypermethylation, or a mismatch repair gene mutation. I think the data has emerged that immunotherapy is here to stay for these patients in the newly diagnosed advanced stage, even chemo naïve, who need adjuvant therapy.   The pMMR population, this is where we're seeing more and more questions emerge because we realize that that may be a cohort of different cancers. And I'll let Shannon speak to this briefly, but even the incorporation of the PARP inhibitor, in addition to the checkpoint, there's a biologic rationale for combining those two together to augment response. And to see the benefit in that trial—arm three and arm two, we can look at descriptively and look at the differences, but who are those patients? Where is the PARP and the checkpoint most effective? How do we expand that to a larger population of patients potentially? These are questions that emerged because, as Dr. Weston will allude to, I know we also talk about HRR mutations, which are captured, but we even have a lot to understand about that in endometrial cancer, where we've had more research in the ovarian cancer space. Dr. Shannon Westin: Being mindful of time, because I have, like, 1,000 hypotheses that have been generated by this study, which, I think, shows it's a great study, right? Because you get some answers, and as our colleague Brad Monk says, “The only definitive study is the negative studies.” This most certainly was not that. But just kind of expanding on what Ramez said, the interesting thing about DUO-E is that really the biggest benefit for the combination of the durvalumab and olaparib was in that mismatch repair proficient group. And I personally thought that we were going to see accentuation of the impact in the mismatch repair deficient group based on the science, but that just wasn't borne out by the data. It doesn't seem that the combination has that much to add in that mismatch repair deficient group. And when we tease out the mismatch repair proficient group, I think that's where a lot of interesting information is going to come because, to Ramez's point, we're going to tease out: Is it driven by the P53-mutant population? Is it driven by the population that has homologous recombination deficiency? How do we even measure homologous recombination deficiency in endometrial cancer? So I'm super excited about what we found and how that may help us to make those decisions for the patient in front of us.  The other thing I think needs to be made mention of—and this was something we saw in DUO-E as well as AtTEnd—we had a large population of patients that were recruited in Asia, 30%. Interestingly, when we look at the forest plot, that group doesn't seem to benefit as much from the addition of the olaparib. So we really need to tease out what's different about that population because what Nicoletta Colombo presented around AtTEnd, it looked like they didn't benefit from the atezolizumab either in that study. So there's clearly something different about that population, and we have a really big opportunity to look at that since we had such a large proportion of patients that were enrolled there. So that's another, I think, really intriguing question. Dr. Lidia Schapira: So how does this fit in the context of endometrial cancer treatment, and what are we going to do with patients in the clinic? I'd love to hear both of your perspectives, starting with you, Ramez. Dr. Ramez Eskander: It's an evolving answer, to say the least. What we can say definitively is that we have a United States FDA approval for the regimen of dostarlimab plus carboplatin and paclitaxel in the mismatch repair deficient, advanced-stage/recurrent or metastatic patient cohort. And again, that's because the magnitude of benefit that we saw in the RUBY trial, which looked at that, was actually analogous to what we saw in 018, AtTEnd, and DUO-E, again, consistently highlighting the benefit of the IO and the dMMR. We have yet to see how this is going to evolve the landscape in the larger patient population, which is the pMMR patient population. And it may be that based on the data that we have, we will see immunotherapy plus carboplatin and paclitaxel as the new standard of care in the pMMR cohort, or it may not. That's yet to be defined. And I think Dr. Westin will add to this, but I think that's also going to depend on the perception of how we view the cohort. Is it one group of patients? Are we going to have to think about subsets within the pMMR population? That is an active conversation. Dr. Shannon Westin: I would just add, having treated patients on this combo regimen with the durvalumab and olaparib, I have multiple patients that still remain on study, and this—we're looking at three and four years out. I just never saw anything like that before with standard chemotherapy, so there's definitely something here. So I want to know who those patients are, who benefits really the best from the combination, and who could we just give the immunotherapy to and get that same benefit. So we obviously always want people to live as long as possible. That's the bottom line. But we don't want to overtreat. And so I think balancing that is really important. Dr. Ramez Eskander: The point that was made earlier: We have yet, aside from MMR response to checkpoint, within the pMMR population, we understand that there may be subsets, but we have yet to prospectively validate that these molecular cohorts within the pMMR population are truly defining response to a particular therapeutic strategy. So we have to be cautious not to limit the treatment opportunities for these patients without having the data that we need to do so because, as Dr. Westin mentioned, for us—whether it was the Gy018 trial, the RUBY, the DUO-E trial—what we saw is there are pMMR patients who have a dramatic response even though they are “biomarker negative.” They're pMMR, they're TMB low, they're not POLE mutated, but yet they still derive a dramatic benefit. And so that goes back to the hypothesis about why we're even combining checkpoint with chemotherapy in which, for example, in lung cancer, there's been established success and approval. So I think we're all eager to see these strategies emerge as treatment opportunities for the pMMR patients as we work to still develop additional effective opportunities. Dr. Lidia Schapira: So, based on all of this and sort of the new twists on the scientific hypotheses that are now generated, what are the next steps? Dr. Shannon Westin: Well, I think we have to see if these drugs are available for patients. So looking at things like compendium listing and regulatory approvals obviously is going to be very important. But from the things that I can control, we are looking at the different molecular subtypes and understanding the different mutation status and trying to tease out who may be driving the biggest benefits so that we can help advise and make sure that we're doing the right thing for the patients. Dr. Lidia Schapira: And wearing my supportive care hat, I have to ask you, Shannon, about the tolerability. We often find that the quality of life and studies come out after, sometimes months or years after, the original trials are published. So let me take this opportunity to ask you now: How did women tolerate these drugs? Dr. Shannon Westin: The bottom line, Lidia, is, as expected, when you add additional drugs, you see additional side-effects. I think the good thing is that we're very comfortable with immunotherapy and we're very comfortable with PARP inhibition in gynecology because we have had access to these agents and so we know how to manage the toxicities. And so, from a standpoint of incidence, there was a higher incidence of grade three and higher adverse events in the group that had durvalumab/olaparib. But this was primarily driven by anemia, which is as expected and is usually pretty time-limited at the start of olaparib. From a long-term standpoint, there was a slightly higher proportion of patients that discontinued therapy, but it actually wasn't as much as I was worried about. So we saw a 19% discontinuation rate in the group that was just the control arm, and that went up to 24% in the dual arm, so definitely higher, but not that much higher. And when we moved to maintenance, which is really where—that's where the arm becomes unique, it was much lower at about 12%. And so that's exciting to me, that patients were able to stay on a drug and were able to tolerate it.  And then, to your other point, we do have a very nice patient-reported outcomes plan, and that is actually being analyzed as we speak with the hope of presenting it at the next major meeting, our Society of GYN Oncology meeting in March. So not right away, but I think in a pretty timely fashion, we'll have those data. Dr. Lidia Schapira: Congratulations, Shannon, on leading and presenting this wonderful study. So it's been a real pleasure to chat with the two of you. Dr. Ramez Eskander: Thank you. Dr. Shannon Westin: Thanks so much, Lidia. I really appreciate it. Thanks, Ramez, for being here.  And I will just say thank you to all of our listeners. We really hope you enjoyed this episode of JCO After Hours, where we discussed the DUO-E trial, which is a phase III trial evaluating durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer. And again, please do enjoy this publication that was online at the Journal of Clinical Oncology on October 21st, 2023. And do check out our other podcast offerings wherever you get your podcasts. Have a wonderful day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Part two of this series features Dr. Daniel Grossman, an obstretrician and gynecologist, and Dr. Katrina Kimport, a sociologist in Obstetrics, Gynecology, and Reproductive Sciences at the University of California at San Francisco. They talk with Dr. Josh Sharfstein about their research documenting cases where patients were denied proper medical care because of abortion restrictions—even when the care was unrelated to a pregnancy. They discuss how being forced to deny proper medical care can cause catastrophic health problems and trauma for pregnant people and their loved ones, as well as distress for the medical professionals involved. For part one of the series, check out episode 656. Read the report here: https://www.ansirh.org/sites/default/files/2023-05/Care%20Post-Roe%20Preliminary%20Findings.pdf

We've come a long way since DNA was first discovered in the mid 19th century. Today's scientists are using powerful engineering techniques to edit genes in human eggs and sperm, curing diseases and repairing defective genes before a child is even born. Some scientists are excited about these therapies, championing them as an exciting opportunity to create immunity to viruses, eliminate serious illnesses like AIDS, Alzheimer's, and cancer, and possibly reverse aging. Like prior innovations in medicine and technology, why wouldn't we embrace a science that allows people to live longer, healthier, and happier lives? Others are alarmed. They are worried that these new techniques raise a host of profound ethical issues. While eliminating genetic diseases is a worthwhile endeavor, many parents might be inclined to use this science to create designer babies: children who are smarter, taller, or have other supposedly desirable traits. And these tools aren't cheap. They will surely be available to the rich first, creating a terrifying new dimension to the growing economic inequality crisis. Scientists also point out that ‘playing god' and editing genes will alter our DNA code forever, and one mistake could inadvertently introduce new diseases into the human gene pool. While the desire to cure genetic diseases is a noble one, the manipulation of our DNA is more likely than not to push humanity towards a dangerous and dystopian future no one wants.  Arguing for the motion is George Church, Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard and MIT Arguing against the motion is Joyce Harper, Professor of Reproductive Science at the Institute for Women's Health, University College London.   Sources:  ABC News, France24, Today Show, NBC News, VICE, PBS, Gattaca, Critical Past The host of the Munk Debates is Rudyard Griffiths - @rudyardg.   Tweet your comments about this episode to @munkdebate or comment on our Facebook page https://www.facebook.com/munkdebates/ To sign up for a weekly email reminder for this podcast, send an email to podcast@munkdebates.com.   To support civil and substantive debate on the big questions of the day, consider becoming a Munk Member at https://munkdebates.com/membership Members receive access to our 10+ year library of great debates in HD video, a free Munk Debates book, newsletter and ticketing privileges at our live events. This podcast is a project of the Munk Debates, a Canadian charitable organization dedicated to fostering civil and substantive public dialogue - https://munkdebates.com/ The Munk Debates podcast is produced by Antica, Canada's largest private audio production company - https://www.anticaproductions.com/ Senior Producer: Ricki Gurwitz Editor: Reza Dahya  

Welcome to our mini-series on Reproductive Justice and Family Planning! Diana Greene Foster, PhD, author of The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having - or Being Denied - an Abortion, sits down with host Tammy Kremer to advocate for reproductive justice and bodily autonomy. She explains that the Turnaway Study found that, “When people are making the decision about what to do with an unexpected pregnancy and they decide on abortion, all the reasons they give us are exactly those outcomes that we see for people who are denied an abortion.” She envisions a world in which “everyone is an equal partner in sex, in childbearing, in contraception, in pregnancy decision-making.”  Download the transcript of this episode. Follow Diana Greene Foster on Twitter. Resources:  The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having—or Being Denied—an Abortion  Global Turnaway Study  ANSIRH: Advancing New Standards in Reproductive Care  Bixby Center for Global Reproductive Health   Plan C Pills  “Black Women's Lived Experiences of Abortion"  Girlx Lab CAPTC-Related Training and Resources:   S3 E9: Abortion and Reproductive Justice Across State Lines     S2 E2: Speaking Frankly: Supporting Youths' Choice to Parent with Dr. Aisha May  Reproductive and Sexual Health Considerations for Trans and Non-Binary People  Turn on notifications to never miss an episode of Coming Together for Sexual Health. Follow Coming Together for Sexual Health on Instagram and Twitter. Diana Greene Foster is a professor at the University of California, San Francisco, in the Department of Obstetrics, Gynecology, and Reproductive Sciences and a researcher at Advancing New Standards in Reproductive Health. She is the principal investigator of the Turnaway Study in the United States and Nepal, a nationwide longitudinal prospective study of the health and well-being of women who seek abortion including both women who do and do not receive abortion.  

This month, the FDA approved the country's first-ever daily hormonal contraceptive pill for sale without a prescription. The approval is a major milestone for reproductive care, as state lawmakers ban or limit abortion access throughout the country. The over-the-counter contraceptive, called Opill, has been around for decades, and now Perrigo, the pill's manufacturer, says it will make the pill “accessible and affordable to women and people of all ages.” We'll look at the science, the politics and the early history of the pill, and we'll hear from you: has the pill changed your life? Guests: Pam Belluck, health and science reporter, New York Times Pratima Gupta, assistant professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSD Health Margaret Marsh, historian of medicine and University Professor, Rutgers University. She's the author, with gynecologist Wanda Ronner, of several books on the history of reproductive medicine and technology, including "The Fertility Doctor: John Rock and the Reproductive Revolution."

Rachel Lehmann-Haupt as an expert on the future of family life, career timing, and the influence of science and technology on fertility, pregnancy, and family. I'm so honored to be hosting her on The Egg Whisperer Show podcast today!   The age of motherhood is on the rise across the developing world, and as a result, many people are becoming increasingly reliant on alternative and creative choices to form their families. And this includes advanced reproductive technologies like egg freezing, in vitro fertilization, the use of donor eggs, and the option to become a "DIY mom," a phrase that Rachel coined.    Rachel is the founder of StoryMade Studio, a boutique content strategy studio advising health and fertility companies. She is a storyteller, author, and have experience with egg freezing, creative family building.    Rachel joins me on the podcast today to talk about the recent book that she's published, "Reconceptions: Modern Relationships, Reproductive Science, and the Unfolding Future of Family."    Tune in on Dr. Aimee's website.   You can find Rachel Lehmann-Haupt's site here. Would you like to ask Dr. Aimee your personal IVF questions? Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, July 31, 2023 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Looking for the best products to support you while you're TTC? Get Dr. Aimee's brand new Conception Kit here.   Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org  where you can schedule a consultation. More ways to connect with Dr. Aimee: Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updatesFollow on Instagram

Join hosts Doctor Xand van Tulleken and Dr Rochelle Burgess for Season 3, Episode 4 of Public Health Disrupted with Prof Joyce Harper and Rachel Lankester. “We're more valuable to our communities post-menopause as leaders than as breeders.” How does our society value menopausal women? The lack of public awareness around this natural phase in a women's life has resulted in the menopause being associated with a lot of shame, and a whole bunch of negative misconceptions. In this thought-provoking episode, Joyce Harper (Professor of Reproductive Science at the UCL Institute for Women's Health) and Rachel Lankester (author of Magnificent Midlife) challenge the prevailing negative narrative surrounding the menopause by debunking common myths, and revealing the surprising beneficial rewards that await women post-menopause. Plus, what can we learn from the whales? For more information and to access the transcript: https://www.ucl.ac.uk/health-of-public/change-demystifying-menopause Date of episode recording: 2023-06-07 Duration: 00:40:00 Language of episode: English Presenter:Xand van Tulleken; Rochelle Burgess Guests: Joyce Harper; Rachel Lankester Producer: Annabelle Buckland

In this episode, I sit down with menopause maven Dr. Mary Jane Minkin, a clinical professor of Ob-Gyn at Yale University, to discuss articles published in the most recent edition of Menopause: The Journal of the North American Menopause Society. We discuss the following 5 articles*:  Treating where it hurts—a randomized comparative trial of vestibule estradiol for postmenopausal dyspareunia Goetsch MF, Garg B, Lillemon J, Clark AL. Treating where it hurts-a randomized comparative trial of vestibule estradiol for postmenopausal dyspareunia. Menopause. 2023 May 1;30(5):467-475. doi: 10.1097/GME.0000000000002162. Epub 2023 Feb 14. PMID: 36787525. The association between hormone therapy and the risk of lung cancer in postmenopausal women: a 16-year nationwide population-based study Wu CC, Chung CH, Tzeng NS, Wu MJ, Tsao CH, Wu TH, Chien WC, Chen HC. The association between hormone therapy and the risk of lung cancer in postmenopausal women: a 16-year nationwide population-based study. Menopause. 2023 May 1;30(5):521-528. doi: 10.1097/GME.0000000000002165. Epub 2023 Feb 27. PMID: 36854166. Effects of menopausal hormone therapy on the risk of ovarian cancer: Yuk JS, Kim M. Effects of menopausal hormone therapy on the risk of ovarian cancer: Health Insurance Database in South Korea-based cohort study. Menopause. 2023 May 1;30(5):490-496. doi: 10.1097/GME.0000000000002176. Epub 2023 Apr 4. PMID: 37022299. Diagnosis, causes, and treatment of dyspareunia in postmenopausal women Streicher LF. Diagnosis, causes, and treatment of dyspareunia in postmenopausal women. Menopause. 2023 Jun 1;30(6):635-649. doi: 10.1097/GME.0000000000002179. Epub 2023 Apr 11. PMID: 37040586. Menopause hormone therapy and urinary symptoms: a systematic review Christmas MM, Iyer S, Daisy C, Maristany S, Letko J, Hickey M. Menopause hormone therapy and urinary symptoms: a systematic review. Menopause. 2023 Jun 1;30(6):672-685. doi: 10.1097/GME.0000000000002187. Epub 2023 May 16. PMID: 37192832. *Please note: I have provided links to the articles, but they are behind a paywall, meaning you will only see a summary.  Mary Jane Minkin MD Website: madameovary.com Mary Jane Minkin, MD, is a clinical professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the Yale University School of Medicine, and has been in private practice in New Haven (CT) for more than 40 years. Dr. Minkin is board-certified in obstetrics and gynecology, and she practices at Yale-New Haven Hospital. She earned her medical degree from Yale Medical School and her undergraduate degree from Brown University. She did her internship and residency at Yale-New Haven Hospital, the former in internal medicine, the latter in obstetrics and gynecology. She is a fellow of the American Congress of Obstetricians and Gynecologists (FACOG) and has been a North American Menopause Society Certified Menopause Practitioner (NCMP) since 2002. Dr. Minkin has been Director of the Sexuality, Intimacy and Menopause clinic in the Division of Gynecological Oncology, in the Smilow cancer center at Yale New Haven Hospital since 2008. She has also been Director of the Yale Obstetrical and Gynecological Society (YOGS) since its inception in 2006. Other episodes that address these topics: Episode 5: Vaginal Estrogen- Rings, Creams, and Other Things Episode 11: Vaginal Estrogen is Not Poison Episode 27:  Using Vaginal Estrogen but Sex Still Hurts Like Hell  Episode 44 A Deep Dive into RECURRENT UTI Episode 74 Ospemifene- A Pill a Day to Keep Dryness Away  Lauren Streicher, MD is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, and the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause. She is a certified menopause practitioner of the North American Menopause Society.  Sign up to receive DR. STREICHER'S FREE NEWSLETTER Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.  Subscribe and Follow Dr. Streicher on  DrStreicher.com Instagram @DrStreich Twitter @DrStreicher Facebook  @DrStreicher YouTube  DrStreicherTV Books by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy

Professor Caroline Gargett, PhD, is a National Health and Medical Research Council of Australia Leadership Fellow, Women's Health Theme Leader and heads the Endometrial Stem Cell Biology Laboratory at the Hudson Institute of Medical Research and an adjunct Professor in the Department of Obstetrics and Gynaecology, Monash University. She discovered endometrial stem/progenitor cells and investigates their role in endometrial biology, endometriosis and is developing a bioengineered cell-based therapy for treating and preventing Pelvic Organ Prolapse using endometrial mesenchymal stem cells and novel biomaterials. Her awards include the Society for Reproductive Investigation President's Achievement Award (2013), the Endometriosis Foundation of America Honoree (2011), Fellow of the Society for Reproductive Biology (2017) and co-recipient of the $1M Magee Prize for a Vaginal Stem Cells Study She is a Director of the National Stem Cell Foundation of Australia and Stem Cells Limited and Scientific Advisory Board member of the Endometriosis Foundation of America, Fondation Pour la Recherche sur Endometriose, France. She was President of the Australasian Society for Stem Cell Research (2013-2014) and Secretary of the Society for Reproductive Biology (2005-2008). She has authored 155 publications. Currently she is an Editorial Board member of Scientific Reports, Reviewing Board Member for Biology of Reproduction and former Editorial Board Member and Associate Editor for Reproductive Sciences. She previously served as Associate Editor for Fertility and Sterility and Human Reproduction. IMPACT OF OUR POP RESEARCHProf Gargett is developing the first cell-based bioengineered therapy for Pelvic Organ Prolapse (POP) using eMSC and new biomaterials. The impact of the knowledge generated in evaluating their new bioengineered therapy in a rat model of “POP” repair (2014) was the initiation of a new line of research in Urogynaecology. She and now others have progressed her pioneering research to large animal vaginal surgery models of POP, nanotechnologies and 3D (bio)printing. She trained 3 gynaecologists in this new technology, one received 3 International awards, was invited to present at a Gordon Research Conference (2016) and leads a research group in Graz, Austria. She secured 3 CIA NHMRC Project, Investigator & SIEF grants for our POP research and given 14 international invited presentations, including The Royal Society, London (2017) and IUGA Clinical Conference (2020, 2019, 2018, 2022) and was invited to join IUGA Steering Committee to create a Basic Science/Translational Research Special Interest Group and presented in the inaugural IUGA Basic Science Symposium in 2020.*******************I recommend checking out my comprehensive pelvic health education and fitness programs on my Buff Muff AppYou can also join my next 28 Day Buff Muff Challenge https://www.vaginacoach.com/buffmuffIf you are feeling social you can connect with me… On Facebook https://www.facebook.com/VagCoachOn Instagram https://www.instagram.com/vaginacoach/On Twitter https://twitter.com/VaginaCoachOn The Web www.vaginacoach.com

Stop Flushing Your Health Data Down The Toilet You could be flushing important information about your health right down the toilet—quite literally. Pee and poop can tell you a lot about your health, so what if your waste…didn't go to waste? What if, instead, it could tell you more about your health? Like number one, it can catch a condition like diabetes early. Or number two, check out what's going on in your gut microbiome. That's the goal of the smart toilet—a device that gets all up in your business to tell you more about your health. Ira talks with the inventor of the PH Smart Toilet, Dr. Seung-min Park, instructor of urology at Stanford's School of Medicine in California, about how the toilet works, how it can be used to catch diseases early on, and the ethical implications of such a device.   50 Years Later, Reflecting On The Treaty That Controls Wildlife Trade 50 years ago this month, a collection of nations met in Washington and reached agreement on a way to regulate international trade in certain wildlife species—from orchids to gorillas. That agreement came to be known as CITES, the Convention on International Trade in Endangered Species of Wild Fauna and Flora. The treaty has come to cover over 30,000 different plants and animals. Some, listed in Appendix 1 of the treaty, are under a complete ban on commercial use, while other species have their trade tightly regulated via a system of permits. Dr. Susan Lieberman, the vice president for international policy at the Wildlife Conservation Society, has attended the last 13 meetings of the CITES signatories. She joins Ira to talk about the convention, and what it has meant for conservation over the last 50 years.   This Skin-like Robot Can Heal Itself Think of a robot, and the image that may come to mind is a big, hulking body building cars or working in factories. They battle each other in the movies. But a growing field called softbotics focuses on thin, flexible materials—closer to human skin than to a Transformer. There's been a breakthrough in this field out of Pittsburgh: softbotics that can not only conduct electricity, but can heal itself from damage. This replicates the healing abilities of organic materials, like skin, but can happen in seconds. Dr. Carmel Majidi, mechanical engineering professor at Carnegie Mellon University, joins Ira to break down possible futures for this material, including a new generation of prosthetics.   Naked Mole-Rats Are Eternally Fertile There may be no stranger—or more impressive—critter than the naked mole-rat. They may look unassuming, but they can defy aging, have an astonishingly high pain tolerance, and are resistant to cancer. And their list of superpowers doesn't stop there. Scientists recently discovered yet another way these rodents reject the mammalian status quo: by producing egg cells, and staying fertile, until the day they die. This makes them unlike humans, whose ovaries eventually stop producing eggs. So what can we learn about fertility from these strange critters? Ira talks with the lead researcher of this study, Dr. Miguel Brieño-Enriquez, assistant professor at the Magee-Womens Research Institute and the University of Pittsburgh School of Medicine's Department of Obstetrics, Gynecology and Reproductive Sciences.   Transcripts for each segment will be available the week after the show airs on sciencefriday.com.    

My guest, Professor Martha Hickey, is Professor of Obstetrics and Gynaecology at the University of Melbourne and Adjunct Professor of Obstetrics, Gynaecology and Reproductive Sciences at Yale University. She is in active clinical practice with a research expertise in menstrual disorders and menopause. This is such an important conversation about normalizing menopause. It may be difficult for some women but it is a completely natural transition in a woman's life. Martha is a leader in developing national guidelines for menopause management in Australia and New Zealand and also in developing a new model of care for managing menopausal symptoms after breast cancer. She was the lead author on an article about normalizing menopause in the British Medical Journal which ruffled a few feathers last summer.  We talk about: - Why her BMJ article proved so contentious - Misinformation about menopause that she'd like to correct - The ‘official' symptoms of menopause - Martha's view on HRT and what it can be used for - Narratives around menopause and HRT in the UK and elsewhere - Working out what's fact in a sea of information - HRT and breast cancer - Martha's Flesh After Fifty exhibition - How older women are viewed in society - Older women in aboriginal art - Martha's hopes for menopause and older women And more!   If you enjoyed this episode, please subscribe, share it and leave us a 5* review on iTunes or wherever you're listening. Order the ebook or audiobook (narrated by Rachel) versions of Rachel's book, Magnificent Midlife: Transform Your Middle Years, Menopause And Beyond at magnificentmidlife.com/book   The paperback can be purchased on Amazon or other online retailers: UK: https://www.amazon.co.uk/Magnificent-Midlife-Transform-Middle-Menopause/dp/173981150X/ US & Canada: https://www.amazon.com/Magnificent-Midlife-Transform-Middle-Menopause/dp/173981150X/ Australia: https://www.amazon.com.au/Magnificent-Midlife-Transform-Middle-Menopause/dp/173981150X/ You can listen to all the other episodes and get the show notes at magnificentmidlife.com/podcast. Recommended by the Sunday Times. Feedspot #3 in best midlife podcasts and #15 in best women over 50 podcasts worldwide. You'll find lots of strategies, support, and resources to help make your midlife magnificent at magnificentmidlife.com. Check out Rachel's online Revitalize Experience, a 6-week intensive small group mentoring experience or 1-1 Midlife Mentoring.   Follow Rachel on: Facebook: facebook.com/magnificentmidlife Instagram: instagram.com/magnificentmidlife Linkedin: linkedin.com/in/rachellankester Twitter: twitter.com/MagnifMidlife Pinterest: pinterest.co.uk/MagnificentMidlife1 Youtube: youtube.com/channel/UCEteu6Z2mW1z1wnHiVB08uw Tiktok: tiktok.com/@magnificent_midlife

I talk with Dr Harvey Kliman about his research and medical opinion when it comes to the placenta, pregnancy loss/stillbirth, & reoccurring pregnancies. He is a research Scientist in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the Yale University of Medicine and the Director of the Reproductive and Placental Research Unit with the following Research Interests: Pregnancy Complications and losses, Autistic Disorder, Endometrium, and Infertility.    Dr Kliman is the one who gave me some answers around Brody's death. He shed some light on what could have happened & how we prevent it from happening again. Without his placenta pathology report, I would still be going off of what my OB said, "he was perfect, this was freak, & it won't happen again." False.Here's what we discuss:His background and how he got hereDeveloping the Estimated Placenta Volume measurementsPushback from doctorsCauses of stillbirthCauses of a small placentaHow to monitor if your placenta is smallHow do approach doctors about EPVC***d & the placentaAnd so much more... Important info from Dr Harvey Kliman:EPV: Estimated Placental VolumePregnancy loss: Pregnancy LossesHome page: Reproductive and Placental Research UnitOrganization: Measure the PlacentaEmail: harvey.kliman@yale.eduThis is an episode for those who are curious about the placenta, who want to find answers, who also want to learn about other things outside of a small placenta, & to hear how we can prevent this from happening again in subsequent pregnancies. ***NOTE: this is always an open platform from the viewpoint of the guest and does not always reflect my beliefs. As always do your own research & use your own judgement on what's best for you. I am not a doctor or a therapist. I am just a real life loss mom describing her experiences with life after loss. This is my real life, and I'm putting it out there so you feel less alone. ***For more REAL TALK about pregnancy loss, stillbirth and grief, hit follow!Instagram https: @thekatherinelazarFacebook: @thekatherinelazarWATCH IT HERE: Youtube: @thekatherinelazarEmail: thekatherinelazar@gmail.comWebsite: www.katherinelazar.com Some helpful resources:https://countthekicks.org/https://www.measuretheplacenta.org/https://www.pushpregnancy.org/https://www.tommys.org/ Follow me on Social Media:Instagram and Facebook: @thekatherinelazar   

Today, I'm joined by two fabulous guests: Marielle Gross, Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh, and renaissance man, Brian Frye, the Spears-Gilbert Professor of Law at the University of Kentucky.  Marielle provides clinical care at UPMC Altoona and her research focuses on the application of technology and elimination of bias as a means of promoting evidence-basis, equity and efficiency in women's healthcare. Today, we're discussing heny, Inc., a start up that Marielle founded that utilizes NFTs to allow breast cancer patients to remain connected to their biopsy results. When patients participate in research studies, their names and identifying features are taken off of their samples – in other words, they are deidentified. What this means is that if researchers find medically relevant information, they can't pass that on to the patient. Nor can patients share in any of the profits that research on their tissue might generate. As we discuss in this episode, Marielle was inspired by the infamous Henrietta Lacks case to create a non-fungible NFT-like token that allows breast cancer patients to track and learn about research on their donated tumor and tissues.  That's where Brian Frye comes in: he teaches courses on patent and intellectural property law, and has published widely about NFTs. Many of his articles are linked in the show notes. Brian is also a filmmaker. He produced the documentary Our Nixon (2013), which was broadcast by CNN and opened theatrically nationwide. His short films and videos have shown in the 2002 Whitney Biennial, the New York Film Festival, and the San Francisco International Film Festival, among other venues, and are in the permanent collection of the Whitney Museum of American Art. If you don't get enough of Brian in this episode, then make sure to listen to my earlier bonus episode: The Plagiarism Taboo with Brian Frye.  Further reading and listening: Marielle S Gross, MD; Amelia J Hood, MA; Robert C Miller Jr, BA, Nonfungible Tokens as a Blockchain Solution to Ethical Challenges for the Secondary Use of Biospecimens: Viewpoint, JMIR Bioinform Biotech 2021;2(1):e29905) doi: 10.2196/29905; https://bioinform.jmir.org/2021/1/e29905 This Pitt professor's startup applies NFTs to bioethics, Technical.ly, Sept. 13, 2022; https://technical.ly/startups/heny-nfts-bioethics-marielle-gross/ The Plagiarism Taboo with Brian Frye, https://www.buzzsprout.com/1227113/episodes/11050801 Frye, Brian L., NFTs & the Death of Art (April 19, 2021). Available at SSRN: https://ssrn.com/abstract=3829399 or http://dx.doi.org/10.2139/ssrn.3829399 Frye, Brian L., How to Sell NFTs Without Really Trying (September 25, 2021). 13 Harvard Journal of Sports and Entertainment Law 113 (2022), Available at SSRN: https://ssrn.com/abstract=3930430 Frye, Brian L., After Copyright: Pwning NFTs in a Clout Economy (November 25, 2021). 45 Colum. J.L.& Arts 341 (2022), Available at SSRN: https://ssrn.com/abstract=3971240 or http://dx.doi.org/10.2139/ssrn.3971240 Frye, Brian L., The Art of the Token (March 16, 2022). Stanford Journal of Blockchain Law & Policy, Available at SSRN: https://ssrn.com/abstract=4059574 

How much do you really know about your fertility, menstrual cycles, and conception? Join us to learn more with Dr. Joyce Harper, a Professor of Reproductive Science at the Institute for Women's Health, University College London, and the head of the Reproductive Science and Society Group. She is the author of  Your Fertile Years.In this episode, we cover:Understanding the menstrual cycleUnderstanding the basic of conceptionPredicting ovulationBasics of InfertilityWhat percentage of infertility is caused by the female partner, the male partner, or both?What causes a woman to not ovulate?Initial workup for women who meet the definition of infertilityWorkup for Recurrent Pregnancy LossTreatment Options for Infertility How does the infertility workup differ for the LGBTQ+ community (Lesbian, Gay, Bisexual, Transgender, Non-binary, Queer, Intersex, Asexual, and Gender Nonconforming Individuals)? This podcast is produced  by www.CreatingaFamily.org. We are a national non-profit with the mission to strengthen and inspire adoptive, foster & kinship parents and the professionals who support them. Creating a Family brings you the following trauma-informed, expert-based content:Weekly podcastsWeekly articles/blog postsResource pages on all aspects of family buildingPlease leave us a rating or review RateThisPodcast.com/creatingafamilySupport the showDo you want more expert-based information? Check out our free resources at CreatingaFamily.org.

We've come a long way since DNA was first discovered in the mid 19th century. Today's scientists are using powerful engineering techniques to edit genes in human eggs and sperm, curing diseases and repairing defective genes before a child is even born. Some scientists are excited about these therapies, championing them as an exciting opportunity to create immunity to viruses, eliminate serious illnesses like AIDS, Alzheimer's, and cancer, and possibly reverse aging. Like prior innovations in medicine and technology, why wouldn't we embrace a science that allows people to live longer, healthier, and happier lives? Others are alarmed. They are worried that these new techniques raise a host of profound ethical issues. While eliminating genetic diseases is a worthwhile endeavor, many parents might be inclined to use this science to create designer babies: children who are smarter, taller, or have other supposedly desirable traits. And these tools aren't cheap. They will surely be available to the rich first, creating a terrifying new dimension to the growing economic inequality crisis. Scientists also point out that ‘playing god' and editing genes will alter our DNA code forever, and one mistake could inadvertently introduce new diseases into the human gene pool. While the desire to cure genetic diseases is a noble one, the manipulation of our DNA is more likely than not to push humanity towards a dangerous and dystopian future no one wants.  Arguing for the motion is George Church, Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard and MIT Arguing against the motion is Joyce Harper, Professor of Reproductive Science at the Institute for Women's Health, University College London. GEORGE CHURCH “If we bring the cost down, help with education, and make sure there's a dialogue that goes on in both directions, then everybody will have access.” JOYCE HARPER “I worry that these technologies will not be accessible to all and I also worry that people will use them for non-medical reasons. We will have a rich-poor divide that will become bigger and bigger as technology advances.” Sources:  ABC News, France24, Today Show, NBC News, VICE, PBS, Gattaca, Critical Past The host of the Munk Debates is Rudyard Griffiths - @rudyardg.   Tweet your comments about this episode to @munkdebate or comment on our Facebook page https://www.facebook.com/munkdebates/ To sign up for a weekly email reminder for this podcast, send an email to podcast@munkdebates.com.   To support civil and substantive debate on the big questions of the day, consider becoming a Munk Member at https://munkdebates.com/membership Members receive access to our 10+ year library of great debates in HD video, a free Munk Debates book, newsletter and ticketing privileges at our live events. This podcast is a project of the Munk Debates, a Canadian charitable organization dedicated to fostering civil and substantive public dialogue - https://munkdebates.com/ The Munk Debates podcast is produced by Antica, Canada's largest private audio production company - https://www.anticaproductions.com/ Senior Producer: Ricki Gurwitz Editor: Reza Dahya